This higher percentage could relate to the content of the questionnaires: fatigue is a frequent and often debilitating symptom in MS that was expected to improve during glatiramer acetate treatment, whereas the documentation of medication and missed DMD doses may be less appealing to patients. This evidence concerns the gene DMD and myeloid sarcoma.